Despite a somewhat ambivalent vote by its advisory panel, the FDA approved a label expansion for Cubist Pharmaceuticals Inc.'s antibiotic Cubicin (daptomycin), which now can be used against infections in the bloodstream and heart valves, as well as skin. (BioWorld Today) Read More
